SCHEMBL6047773

SCHEMBL6047773

COc1ccc2nc(C(=O)C(C)(C)C)n(C(C)C(=O)O)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.45
BRD4 O60885 1/20 0.40
PTGS2 P35354 3/20 0.39
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
PTGS1 P23219 2/20 0.39
CDC42 P60953 1/20 0.39
RAC1 P63000 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PAX8 Q06710 1/20 0.39
ATM Q13315 1/20 0.39
MTNR1A P48039 2/20 0.38
MTNR1B P49286 2/20 0.38
ACSS2 Q9NR19 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6047840 0.91 ALDH1A1 (0.45) KDM4EPOLBBRD4PTGS2AKR1C3
SCHEMBL4693966 0.77 MTNR1A (0.46) MTNR1AMTNR1BACSS2
SCHEMBL4699300 0.76 MTNR1A (0.47) MTNR1AMTNR1BACSS2ALDH1A1
SCHEMBL4695908 0.76 MTNR1A (0.42) KDM4EPOLBBRD4MTNR1AMTNR1B
SCHEMBL4788547 0.76 POLB (0.37) KDM4EPOLBBRD4MEN1KMT2A
SCHEMBL4696635 0.74 BRD4 (0.53) POLBBRD4MTNR1AMTNR1BACSS2
SCHEMBL4788551 0.74 MTNR1A (0.47) BRD4MTNR1AMTNR1BALDH1A1
SCHEMBL4696828 0.74 MTNR1A (0.48) POLBMTNR1AMTNR1BACSS2ALDH1A1
SCHEMBL4788556 0.73 BRD4 (0.43) KDM4EBRD4MEN1KMT2AMTNR1A
SCHEMBL6047756 0.73 MTNR1A (0.41) POLBBRD4MEN1KMT2AMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148805-A1 Opthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-07-06 US claimed
US-20060148805-A1 Opthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148805-A1 Opthalmic compositions for treating ocular hypertension KCNH2, KCNH3, KCNN1 KDM4E 2009/4885POLB 3975/4885BRD4 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.